This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2003, p. 1963-1967, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.1963-1967.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis

Ellie J. C. Goldstein,1,2* Diane M. Citron,1 C. Vreni Merriam,1 Yumi Warren,1 Kerin L. Tyrrel,1 and Helen Fernandez1

R. M. Alden Research Laboratory, Santa Monica, California 90404,1 University of California at Los Angeles School of Medicine, Los Angeles, California 900732

Received 17 October 2002/ Returned for modification 21 February 2003/ Accepted 10 March 2003

A study of the comparative in vitro activity of telithromycin, a new ketolide, against 155 aerobic and 171 anaerobic antral sinus puncture isolates showed it to be active against a broad range of sinus pathogens. All pneumococci, including erythromycin-resistant strains, were susceptible to telithromycin at <=0.5 µg/ml; all Haemophilus influenzae and Eikenella corrodens strains were inhibited by <=4 µg of telithromycin/ml; all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by <=0.25 and 0.5 µg of telithromycin/ml, respectively. Among all anaerobes tested, 94% (160 of 171 strains) were susceptible to <=4 µg of telithromycin/ml; however, 8 of 17 (47%) Fusobacterium strains, 2 Veillonella strains, and 1 Peptostreptococcus micros strain required >4 µg of telithromycin/ml for inhibition. Telithromycin may offer a therapeutic alternative for sinus infections, including those due to erythromycin-resistant pneumococci.

* Corresponding author. Mailing address: 2021 Santa Monica Blvd., Ste. 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.

Antimicrobial Agents and Chemotherapy, June 2003, p. 1963-1967, Vol. 47, No. 6
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.6.1963-1967.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Brook, I., Hausfeld, J. N. (2005). Recovery of Interfering Bacteria in the Nasopharynx following Antimicrobial Therapy of Acute Maxillary Sinusitis with Telithromycin or Amoxicillin-Clavulanate. Antimicrob. Agents Chemother. 49: 4793-4794 [Abstract] [Full Text]  
  • Chollet, R., Chevalier, J., Bryskier, A., Pages, J.-M. (2004). The AcrAB-TolC Pump Is Involved in Macrolide Resistance but Not in Telithromycin Efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob. Agents Chemother. 48: 3621-3624 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»